OMC Financial Services LTD Invests $695,000 in Quest Diagnostics Incorporated $DGX

OMC Financial Services LTD bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,279 shares of the medical research company’s stock, valued at approximately $695,000.

Several other large investors have also recently made changes to their positions in DGX. Vanguard Group Inc. raised its position in shares of Quest Diagnostics by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company’s stock worth $2,497,458,000 after acquiring an additional 140,450 shares during the period. State Street Corp grew its position in shares of Quest Diagnostics by 3.0% during the 4th quarter. State Street Corp now owns 5,382,547 shares of the medical research company’s stock valued at $934,033,000 after acquiring an additional 158,617 shares during the period. Boston Partners grew its position in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after acquiring an additional 997,033 shares during the period. Morgan Stanley increased its stake in shares of Quest Diagnostics by 17.8% in the 4th quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock valued at $467,415,000 after purchasing an additional 406,658 shares in the last quarter. Finally, EdgePoint Investment Group Inc. increased its stake in shares of Quest Diagnostics by 35.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after purchasing an additional 582,797 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Price Performance

NYSE:DGX opened at $234.48 on Monday. The stock has a 50 day moving average of $215.60 and a two-hundred day moving average of $203.32. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $240.13. The firm has a market cap of $25.88 billion, a P/E ratio of 24.89, a price-to-earnings-growth ratio of 2.16 and a beta of 0.56. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts expect that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be issued a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 dividend on an annualized basis and a yield of 1.5%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the sale, the senior vice president owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 19,747 shares of company stock valued at $3,947,088 in the last 90 days. 0.88% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Barclays upped their target price on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Truist Financial lifted their price target on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. UBS Group upped their price objective on shares of Quest Diagnostics from $220.00 to $232.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Finally, Weiss Ratings raised shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.31.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.